Dyne Therapeutics, Inc (DYN) Stock Analysis
Verdict: AVOID
Dyne's $893M cash funds FORCE platform trials into 2028, but accelerating burn and heavy insider dumping make risk/reward unfavorable.
Investment score: 37/100
Analysis as of
Is Dyne Therapeutics, Inc stock worth reviewing? The TradeMates thesis
Pre-revenue clinical-stage biotech with $893.4M in cash facing accelerating annual cash burn (-$405.1M FCF in 2025) and heavy corporate insider selling. Highly speculative outlook contingent on clinical trial readouts.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 15/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Dyne Therapeutics, Inc opportunities and risks
What speaks for DYN
- FORCE Platform Tissue Targeting Delivery
What speaks against DYN
- Accelerating FCF Burn and Share Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| DYN | n/a | 0.0x | n/a | 0.0% | 0.0% | -15.0% |
| VKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.9% |
| GRAL | n/a | 20.3x | n/a | -10.8% | -236.9% | -8.8% |
| LEGN | n/a | 2.6x | n/a | 56.6% | -7.2% | -7.8% |
| ARQT | 113.9x | 6.8x | 73.1x | 91.1% | 6.1% | 1.2% |
| DNLI | n/a | 903.6x | n/a | -61.0% | -14191.2% | -13.4% |
| Peer median | n/a | 6.8x | n/a | 0.0% | -7.2% | -8.8% |
Frequently asked questions about Dyne Therapeutics, Inc (DYN)
Is DYN stock a good investment?
The TradeMates model rates Dyne Therapeutics, Inc as AVOID with an investment score of 37/100. Pre-revenue clinical-stage biotech with $893.4M in cash facing accelerating annual cash burn (-$405.1M FCF in 2025) and heavy corporate insider selling. Highly speculative outlook contingent on clinical trial readouts. This is algorithmic model output, not personal investment advice.
Is DYN stock a buy?
The TradeMates model verdict for DYN is AVOID with an investment score of 37/100. Treat this as a model signal to review, not a personal buy recommendation.